PURPOSE: The purposes of this study were to investigate the pattern of relapse in patients with low- or intermediate-risk prostate cancer treated with 19-Gy high-dose-rate brachytherapy (HDR-BT) and to calculate the dose received by the area of recurrence. METHODS AND MATERIALS: Patients included in this analysis were treated under a Phase II randomized trial that evaluated the role of 19-Gy HDR-BT monotherapy in low- and intermediate-risk prostate cancers. Multiparametric prostate MRI and prostate biopsy were performed in patients with suspicious local recurrence. The site of local relapse was compared with the initial site of disease. The dose received by the site of recurrence was investigated through registration of the posttreatment multiparametric prostate MRI with the HDR-BT treatment plan. RESULTS: Eight of 87 treated patients were found to have local recurrence after 19-Gy HDR-BT. Seven of the eight recurrences were at the site of initial bulk disease. Seven patients were found to have a more aggressive histology in the posttreatment biopsy. The mean volume of prostate that had received 100% of prescription dose was 97%. Mean dose to area of recurrence was 29.1 Gy, whereas dose to 98% and dose to 90% of the recurrence were 21.6 Gy and 23.2 Gy, respectively. CONCLUSIONS: The relapse pattern after a single 19-Gy HDR-BT is predominantly associated with the site of initial disease. This lends some rationale to future strategies of further focused dose escalation to initial site of disease, notwithstanding the fact that the calculated biologically equivalent dose using linear-quadratic assumptions is already very high.
PURPOSE: The purposes of this study were to investigate the pattern of relapse in patients with low- or intermediate-risk prostate cancer treated with 19-Gy high-dose-rate brachytherapy (HDR-BT) and to calculate the dose received by the area of recurrence. METHODS AND MATERIALS: Patients included in this analysis were treated under a Phase II randomized trial that evaluated the role of 19-Gy HDR-BT monotherapy in low- and intermediate-risk prostate cancers. Multiparametric prostate MRI and prostate biopsy were performed in patients with suspicious local recurrence. The site of local relapse was compared with the initial site of disease. The dose received by the site of recurrence was investigated through registration of the posttreatment multiparametric prostate MRI with the HDR-BT treatment plan. RESULTS: Eight of 87 treated patients were found to have local recurrence after 19-Gy HDR-BT. Seven of the eight recurrences were at the site of initial bulk disease. Seven patients were found to have a more aggressive histology in the posttreatment biopsy. The mean volume of prostate that had received 100% of prescription dose was 97%. Mean dose to area of recurrence was 29.1 Gy, whereas dose to 98% and dose to 90% of the recurrence were 21.6 Gy and 23.2 Gy, respectively. CONCLUSIONS: The relapse pattern after a single 19-Gy HDR-BT is predominantly associated with the site of initial disease. This lends some rationale to future strategies of further focused dose escalation to initial site of disease, notwithstanding the fact that the calculated biologically equivalent dose using linear-quadratic assumptions is already very high.
Authors: Benedict Oerther; Moritz V Buren; Christina M Klein; Simon Kirste; Nils H Nicolay; Tanja Sprave; Simon Spohn; Deepa Darshini Gunashekar; Leonard Hagele; Lars Bielak; Michael Bock; Anca-L Grosu; Fabian Bamberg; Matthias Benndorf; Constantinos Zamboglou Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Constantinos Zamboglou; Christina Marie Klein; Benedikt Thomann; Thomas Franz Fassbender; Hans C Rischke; Simon Kirste; Karl Henne; Natalja Volegova-Neher; Michael Bock; Mathias Langer; Philipp T Meyer; Dimos Baltas; Anca L Grosu Journal: Radiat Oncol Date: 2018-04-12 Impact factor: 3.481
Authors: Finbar Slevin; Samantha Hodgson; Sree Lakshmi Rodda; Peter Bownes; David Bottomley; Ese Adiotomre; Bashar Al-Qaisieh; Emma Dugdale; Oliver Hulson; Joshua Mason; Jonathan Smith; Ann M Henry Journal: Clin Transl Radiat Oncol Date: 2020-03-27
Authors: Constantinos Zamboglou; Matthias Eiber; Thomas R Fassbender; Matthias Eder; Simon Kirste; Michael Bock; Oliver Schilling; Kathrin Reichel; Uulke A van der Heide; Anca L Grosu Journal: Phys Imaging Radiat Oncol Date: 2018-11-05
Authors: Ioannis Androulakis; Rob M C Mestrom; Miranda E M C Christianen; Inger-Karine K Kolkman-Deurloo; Gerard C van Rhoon Journal: Sensors (Basel) Date: 2022-02-09 Impact factor: 3.576
Authors: Damián Guirado; Samuel Ruiz-Arrebola; Ana M Tornero-López; Jose M de la Vega; Pedro J Prada; Antonio M Lallena Journal: J Contemp Brachytherapy Date: 2020-04-18
Authors: Hannah M Dahn; Patricia A K Oliver; Stefan Allen; Amanda Cherpak; Alasdair Syme; Nikhilesh Patil; David Bowes Journal: Adv Radiat Oncol Date: 2019-05-21